Recombinant human GFRA3 protein

(HB8895)
Technical documents: Datasheet

Product overview

Name Recombinant human GFRA3 protein
Alternative names Recombinant Human GDNF Family Receptor Alpha 3, GDNF Family Receptor Alpha3, GDNFR-alpha-3, GFR-alpha-3, GDNF Receptor Alpha-3, GDNFR3, GDNF Family Receptor Alpha-3, Glial Cell Line-Derived Neurotrophic Factor Receptor Alpha-3, GPI-Linked Receptor.
Purity >85%
Description Recombinant human GDNF receptor alpha-3 protein
Write Your Own Review
You're reviewing:Recombinant human GFRA3 protein
Rate this item:

Solubility & Handling

Handling
  • Solutions should be made in sterile deionized water (not less than 100 µg/ml). This solution can then be further diluted with other aqueous solutions.
  • Following reconstitution, solutions may be stored at 4°C and are useable for around 2-7 days and for future use store at -18°C.
  • For long term storage, a carrier protein (0.1% HSA or BSA) should be added to stock solutions. Solutions should be aliquoted into tightly sealed vials for storage at -20°C. Freeze-thaw cycles should be prevented.
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >85%
Source E. Coli.
Appearance Clear solution (sterile filtered)
Formulation Solution (1mg/ml) containing Tris-HCl buffer (20mM, pH 8.0), 0.4M urea and 10% glycerol

References for Recombinant human GFRA3 protein

References are publications that support the biological activity of the product
  • Biology of GDNF and its receptors - Relevance for disorders of the central nervous system

    Ibanez CF et al (2017) Neurobiol Dis 97(Pt B) : 80-89
  • Glial cell line-derived neurotrophic factor (GDNF) induces neuritogenesis in the cochlear spiral ganglion via neural cell adhesion molecule (NCAM)

    Euteneuer S et al (2013) Mol Cell Neurosci 54 : 30-43
  • Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease

    Grondin R et al (1998) J Neurol 245(11 Suppl 3) : P35-42

3 Item(s)